Clinical Trial Detail

NCT ID NCT02932956
Title Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) (GAP)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Baylor College of Medicine
Indications

liver cancer

Advanced Solid Tumor

Therapies

Cyclophosphamide + Fludarabine

Anti-GPC3-scFvGC33-CAR autologous T Lymphocytes

Age Groups: adult child

No variant requirements are available.